Lyell Immunopharma Share Price Today
(NASDAQ: LYEL)

Name: Lyell Immunopharma Share Price Today (NASDAQ: LYEL) - Lyell Immunopharma Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Lyell Immunopharma share price is $0.7 & ₹60.95 as on 6 Mar 2025, 2.30 'hrs' IST

$0.7

Market is closed - opens 8 PM, 06 Mar 2025

View live Lyell Immunopharma share price in Dollar and Rupees. Guide to invest in Lyell Immunopharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Lyell Immunopharma, along with analyst recommendations, forecasts, and comprehensive financials.

Lyell Immunopharma share price movements

Today's Low: $0.69
Today's High: $0.72
$0.70
1.43%
Downside
Day's Volatility :4.3%
Upside
2.91%
52 Weeks Low: $0.51
52 Weeks High: $3.15
$0.70
27.26%
Downside
52 Weeks Volatility :83.81%
Upside
77.74%

Lyell Immunopharma (LYEL) Returns

Period	Lyell Immunopharma, Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-23.91%	3.7%	0.0%
6 Months	-45.31%	-2.8%	0.0%
1 Year	-73.48%	2.5%	0.0%
3 Years	-89.6%	12.9%	-11.6%

Lyell Immunopharma (LYEL) Key Statistics

in dollars & INR

Previous Close	$0.7036
Open	$0.7162
Today's High	$0.721
Today's Low	$0.69
Market Capitalization	$205.6M
Today's Volume	$613.3K
52 Week High	$3.145
52 Week Low	$0.5092
Revenue TTM	$63.0K
EBITDA	$-196.6M
Earnings Per Share (EPS)	$-0.84
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-33.22%

How to invest in Lyell Immunopharma Stock (LYEL) from India?

It is very easy for Indian residents to invest directly in Lyell Immunopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Lyell Immunopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Lyell Immunopharma or LYEL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Lyell Immunopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Lyell Immunopharma shares which would translate to 1.244 fractional shares of Lyell Immunopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Lyell Immunopharma, in just a few clicks!

Returns in Lyell Immunopharma (LYEL) for Indian investors in Rupees

The Lyell Immunopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Lyell Immunopharma investment value today

Current value as on today

₹31,580

Returns

₹68,420

(-68.42%)

Returns from Lyell Immunopharma Stock

₹73,485 (-73.48%)

Dollar Returns

₹5,065 (+5.06%)

Indian investors sentiment towards Lyell Immunopharma (LYEL)

-26%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Lyell Immunopharma Stock from India on INDmoney has decreased by -26% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Lyell Immunopharma

MWG Management Ltd.
6.90%
Orland Properties Ltd
5.17%
BlackRock Inc
4.54%
Decheng Capital LLC
4.08%
Vanguard Group Inc
3.34%
Foresite Capital Management IV, LLC
2.85%

Analyst Recommendation on Lyell Immunopharma

Buy

70%Buy

30%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Lyell Immunopharma(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Lyell Immunopharma Stock (LYEL)

What analysts predicted

Upside of 14.29%

Target:

$0.80

Current:

$0.70

Insights on Lyell Immunopharma Stock (Ticker Symbol: LYEL)

Price Movement
In the last 1 month, LYEL stock has moved up by 18.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 3.0K → 34.0K (in $), with an average increase of 69.3% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -60.66M → -44.58M (in $), with an average increase of 17.6% per quarter
LYEL vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 140.0%
LYEL vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 140.9%

LYEL Lyell Immunopharma Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$657.0K	-
Net Income	$-121.3M	-
Net Profit Margin	-18.5K%	-

	FY20	Y/Y Change
Revenue	$7.8M	↑ 1080.52%
Net Income	$-198.5M	↑ 63.73%
Net Profit Margin	-2.6K%	↑ 15896.28%

	FY21	Y/Y Change
Revenue	$10.7M	↑ 37.31%
Net Income	$-285.5M	↑ 43.81%
Net Profit Margin	-2.7K%	↓ 121.03%

	FY22	Y/Y Change
Revenue	$84.7M	↑ 695.15%
Net Income	$-4.8M	↓ 98.33%
Net Profit Margin	-5.61%	↑ 2675.15%

	FY23	Y/Y Change
Revenue	$130.0K	↓ 99.85%
Net Income	$-234.6M	↑ 4835.46%
Net Profit Margin	-180.5K%	↓ 180480.54%

	Q2 FY23	Q/Q Change
Revenue	$27.0K	↓ 58.46%
Net Income	$-63.9M	↓ 51.83%
Net Profit Margin	-236.6K%	↓ 32583.48%

	Q3 FY23	Q/Q Change
Revenue	$25.0K	↓ 7.41%
Net Income	$-50.9M	↓ 20.41%
Net Profit Margin	-203.4K%	↑ 33217.63%

	Q4 FY23	Q/Q Change
Revenue	$13.0K	↓ 48.0%
Net Income	$-52.9M	↑ 4.08%
Net Profit Margin	-407.2K%	↓ 203741.85%

	Q1 FY24	Q/Q Change
Revenue	$3.0K	↓ 76.92%
Net Income	$-60.7M	↑ 14.62%
Net Profit Margin	-2.0M%	↓ 1615079.48%

	Q2 FY24	Q/Q Change
Revenue	$13.0K	↑ 333.33%
Net Income	$-45.8M	↓ 24.49%
Net Profit Margin	-352.4K%	↑ 1669856.41%

	Q3 FY24	Q/Q Change
Revenue	$34.0K	↑ 161.54%
Net Income	$-44.6M	↓ 2.68%
Net Profit Margin	-131.1K%	↑ 221250.45%

	FY19	Y/Y Change
Profit	$657.0K	-

	FY20	Y/Y Change
Profit	$281.0K	↓ 57.23%

	FY21	Y/Y Change
Profit	$-3.9M	↓ 1482.56%

	FY22	Y/Y Change
Profit	$68.2M	↓ 1855.88%

	FY23	Y/Y Change
Profit	$130.0K	↓ 99.81%

	Q2 FY23	Q/Q Change
Profit	$-4.5M	↓ 9.07%

	Q3 FY23	Q/Q Change
Profit	$-5.1M	↑ 12.57%

	Q4 FY23	Q/Q Change
Profit	$-5.0M	↓ 0.69%

	Q1 FY24	Q/Q Change
Profit	$-5.0M	↓ 0.46%

	Q2 FY24	Q/Q Change
Profit	$-4.9M	↓ 2.65%

	Q3 FY24	Q/Q Change
Profit	$34.0K	↓ 100.7%

	FY19	Y/Y Change
Operating Cash Flow	$39.5M	-
Investing Cash Flow	$-422.4M	-
Financing Cash Flow	$351.2M	-

	FY20	Y/Y Change
Operating Cash Flow	$-160.9M	↓ 507.54%
Investing Cash Flow	$-273.5M	↓ 35.25%
Financing Cash Flow	$476.8M	↑ 35.78%

	FY21	Y/Y Change
Operating Cash Flow	$-126.2M	↓ 21.52%
Investing Cash Flow	$-121.6M	↓ 55.55%
Financing Cash Flow	$401.2M	↓ 15.84%

	FY22	Y/Y Change
Operating Cash Flow	$-169.6M	↑ 34.3%
Investing Cash Flow	$-11.5M	↓ 90.51%
Financing Cash Flow	$10.6M	↓ 97.35%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-39.2M	↓ 15.26%
Investing Cash Flow	$152.9M	↑ 375.56%
Financing Cash Flow	$1.2M	↓ 1833.33%

Lyell Immunopharma Technicals Summary

Sell

Neutral

Buy

Lyell Immunopharma is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Lyell Immunopharma (LYEL) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Lyell Immunopharma, Inc	16.14%	-45.31%	-73.48%	-89.6%	-95.86%
Regeneron Pharmaceuticals, Inc.	-1.42%	-40.28%	-29.31%	11.08%	44.83%
Beone Medicines Ltd	17.63%	36.87%	64.37%	45.89%	71.3%
Vertex Pharmaceuticals Incorporated	1.94%	4.92%	19.37%	108.73%	123.83%
Alnylam Pharmaceuticals, Inc.	-8.03%	-0.89%	66.53%	52.9%	126.66%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Lyell Immunopharma, Inc	1.78	NA	NA	-0.58	-0.33	-0.19	NA	2.07
Regeneron Pharmaceuticals, Inc.	17.86	17.86	1.01	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.34	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Lyell Immunopharma, Inc	Buy	$205.6M	-95.86%	1.78	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$73.8B	44.83%	17.86	31.07%
Beone Medicines Ltd	NA	$29.1B	71.3%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.9B	123.83%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	126.66%	NA	-12.37%

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Organization	Lyell Immunopharma
Employees	224
CEO	Dr. Lynn Seely M.D., Ph.D.
Industry	Services

Management People of Lyell Immunopharma

Name	Title
Dr. Richard D. Klausner M.D.	Founder & Executive Chairman
Dr. Lynn Seely M.D., Ph.D.	President, CEO & Director
Mr. Charles W. Newton	Chief Financial Officer
Mr. Stephen J. Hill	Chief Operating Officer
Dr. Gary Lee Ph.D.	Chief Scientific Officer
Mr. Matthew Lang J.D.	Chief Business Officer, Chief Legal Officer & Corporate Secretary
Prof. Stanley R. Riddell M.D.	Founder & Scientific Advisor
Dr. Crystal L. Mackall M.D.	Founder & Scientific Advisor
Nellie Dillery	Director of Accounting
Ms. Ellen Rose	Senior Vice President of Communications & Investor Relations

Important FAQs about investing in LYEL Stock from India :

What is Lyell Immunopharma share price today?

Lyell Immunopharma share price today stands at $0.70, Open: $0.72 ; Previous Close: $0.70 ; High: $0.72 ; Low: $0.69 ; 52 Week High: $3.15 ; 52 Week Low: $0.51.

The stock opens at $0.72, after a previous close of $0.70. The stock reached a daily high of $0.72 and a low of $0.69, with a 52-week high of $3.15 and a 52-week low of $0.51.

Can Indians buy Lyell Immunopharma shares?

Yes, Indians can invest in the Lyell Immunopharma (LYEL) from India.

With INDmoney, you can buy Lyell Immunopharma at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Lyell Immunopharma at zero transaction cost.

How can I buy Lyell Immunopharma shares from India?

It is very easy to buy Lyell Immunopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Lyell Immunopharma (LYEL) be purchased?

Yes, you can buy fractional shares of Lyell Immunopharma with INDmoney app.

What are the documents required to start investing in Lyell Immunopharma stocks?

To start investing in Lyell Immunopharma, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.